


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Peptide derivatives~~ A peptide compound of formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,

X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ is one or more α-aminocarboxylic acid residue(s), the α-aminocarboxylic acid residue(s) having a length of 500 to 2500 pm


wherein

the amino acids mentioned ~~can also be~~ are optionally derivatized,

the D and the L forms of the optically active amino acid residues are included,

~~and their~~ or a physiologically acceptable salts salt and solvates or solvate thereof.

2. (Currently Amended) ~~Peptide derivatives~~ A peptide compound according to claim 1, of formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,

X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ ~~is absent or~~ is 1-10 amino acids selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and

~~H₂N-(CH₂CH₂O)_m-(CH₂)_m-COOH~~ H₂N-(CH₂CH₂O)_m-(CH₂)_n-COOH,

m,n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12,

with the proviso that m + n > 0

wherein

~~the amino acids mentioned can also be~~ are optionally derivatized,

~~the D and the L forms of the optically active amino acid residues are included, and their or a physiologically acceptable salts salt and solvates or solvate thereof.~~

3. **(Currently Amended)** ~~Peptide compounds~~ A peptide compound according to Claim 1 selected from the group consisting of

cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),

~~and their or a physiologically acceptable salts salt and solvates or a solvate thereof.~~

4. – 6. **(Canceled)**

7. **(Currently Amended)** ~~Pharmaceutical~~ A pharmaceutical preparation[,], comprising

at least one ~~medicament~~ compound according to Claim 5 ~~1~~ and ~~[,] if appropriate,~~
~~vehicles and/or excipients and, if appropriate, other active compounds~~ a vehicle, an
excipient or an active ingredient.

8. **(Withdrawn, Currently Amended)** ~~Use of~~ A method for the treatment or
prevention of a disorder related to the function of an $\alpha_v\beta_6$ integrin receptor, said method
comprising administering a peptide compounds compound according to ~~of~~ Claim 1
and/or their physiologically acceptable salts for producing a medicament for the control
of disorders which are based on expression and pathological function of $\alpha_v\beta_6$ integrin
receptors.

9. **(Withdrawn, Currently Amended)** ~~Use~~ A method according to claim 8 ~~for~~
~~producing a medicament comprising administering said peptide compound~~ for the
control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis,
tumours tumors, osteoporosis, fibrosis, inflammation, infections, psoriasis and or for
influencing wound healing process.

10. **(New)** A compound according to claim 1, wherein R^1 has a length of 600 to 2500
pm.

11. **(New)** A compound according to claim 1, wherein R^1 has a length of 600 to
2000 pm.

12. **(New)** A compound according to claim 1, wherein amino acids which form R^1 are
selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse,
Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and
 $H_2N-(CH_2CH_2O)_m-(CH_2)_n-COOH$.

13. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr.

14. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, and X^2 is
Leu.

15. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, and X^3 is Asp or D-Asp.
16. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, X^3 is Asp or D-Asp, and X^4 is Gly or Ala.
17. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, X^3 is Asp or D-Asp, X^4 is Gly or Ala, and X^5 is Leu.
18. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, X^3 is Asp or D-Asp, X^4 is Gly, Ala or Ser, X^5 is Leu, and X^6 is Arg.
19. **(New)** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, X^3 is Asp or D-Asp, X^4 is Gly, Ala or Ser, X^5 is Leu, X^6 is Arg, and R^1 is 1-10 amino acids selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and $H_2N-(CH_2CH_2O)_m-(CH_2)_n-COOH$, m and n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, and $m + n$ is > 0 .
20. **(New):** A compound according to claim 1, wherein X^1 is Gly or Thr, X^2 is Leu, X^3 is Asp or D-Asp, X^4 is Gly, Ala or Ser, X^5 is Leu, X^6 is Arg, and R^1 is 1-6 amino acids selected from the group consisting of Gly, β -Ala, Abu or Aha.
21. **(New)** A diagnostic agent comprising a peptide compound of claim 1 conjugated to a biological marker.
22. **(New)** A diagnostic agent of claim 21, wherein said marker is biotinyl radical or a fluorescent dye radical.
23. **(New)** A diagnostic agent of claim 21, wherein said marker is a GFP or an antibody.